Roche vet Jean-Jacques Garaud woos international believers in his French startup's take on septic shock
When Jean-Jacques Garaud left the top role in research and early development at Roche to build and advise early-stage biotechs in his native Paris, one fledgling quickly drew close to his heart.
The startup, Inotrem, was developing an immunotherapy to treat septic shock. Having trained as a critical care physician before moving to Schering-Plough and then Novartis, Garaud was all too familiar with the dearth of treatments for sepsis, which is deadly even in developed countries, claiming more than a quarter-million deaths in the US each year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.